Accepted Manuscript. Frank I. Scott, Siddharth Singh. S (19) DOI: Reference: YJCGH 56282
|
|
- Lucas Watts
- 5 years ago
- Views:
Transcription
1 Accepted Manuscript Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win Frank I. Scott, Siddharth Singh PII: S (19) DOI: Reference: YJCGH To appear in: Clinical Gastroenterology and Hepatology Accepted Date: 28 December 2018 Please cite this article as: Scott FI, Singh S, Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win, Clinical Gastroenterology and Hepatology (2019), doi: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
2 Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win Frank I. Scott 1, Siddharth Singh 2,3 1 Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; 2 Division of Gastroenterology and 3 Division of Biomedical Informatics, University of California San Diego, La Jolla, California Running title: Combination Therapy in Inflammatory Bowel Diseases Corresponding author Frank I. Scott, MD MSCE Assistant Professor of Medicine Division of Gastroenterology and Hepatology University of Colorado School of Medicine E. 17th Ave. B158 Aurora, CO frank.i.scott@ucdenver.edu Phone: Fax: Siddharth Singh, MD, MS Assistant Professor of Medicine, Division of Gastroenterology and Division of Biomedical Informatics University of California San Diego 9452 Medical Center Dr. ACTRI 1W501, La Jolla, CA sis040@ucsd.edu Phone: Fax: Word count: Manuscript 1313 References: 20 Funding: This work was supported, in part, by NIH/NIDDK grant K08 DK (FIS) and NIH/NIDDK grant K23-DK (SS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Conflicts of Interest: Frank Scott Research grants from the NIH/NIDDK, Janssen Pharmaceuticals, and Takeda Pharmaceuticals USA; personal fees from PRIME Incorporated, Janssen Pharmaceuticals, and Merck Pharmaceuticals; Siddharth Singh Research grants from the NIH/NIDDK, American College of Gastroenterology, the Crohn s and Colitis Foundation, International Organization for the Inflammatory Bowel Diseases, AbbVie and Pfizer; consulting fees from Takeda, AbbVie. Author Contribution: Frank Scott and Siddharth Singh were involved in drafting and critically revising the manuscript, and approving the final manuscript 1
3 Combination therapy with tumor necrosis factor (TNF)-α antagonists and immunomodulators like thiopurines or methotrexate has been recommended by the American Gastroenterological Association over TNFα-antagonist monotherapy for induction of clinical remission in patients with moderate-to-severe Crohn s disease (CD). These guidelines do not make clear recommendations regarding combination therapy for maintenance of remission, however. 1 The evidence for this was derived from the landmark SONIC trial, in which biologicand immunomodulator-naive patients with recently diagnosed CD (median disease duration, 2.2y) treated with combination therapy of infliximab and azathioprine achieved greater rates of both steroid-free remission and mucosal healing by week 26, compared to monotherapy with infliximab or azathioprine 2. While SONIC was not designed to study maintenance of remission, continued benefit was noted in exploratory analyses up to 50 weeks. However, these findings were not confirmed in COMMIT (Combination of Maintenance Methotrexate-Infliximab Trial), which failed to show benefit of combination infliximab and methotrexate for maintenance of remission 3. Similar negative findings were noted in DIAMOND (Deep Remission of Immunomodulator and Adalimumab Combination Therapy for Crohn s Disease) which assessed adalimumab and thiopurines for induction and maintenance of corticosteroid-free clinical remission over biologic monotherapy. 3, 4 In contrast to CD, there are no longer-term clinical trials comparing biologic-based combination therapy and biologic monotherapy in patients with moderate-severe ulcerative colitis (UC); UC-SUCCESS (Infliximab, Azathioprine, or Infliximab + Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis) demonstrated higher rates of achieving clinical remission, but no endoscopic remission, at week 16 with combination therapy. However, the trial was terminated prior to recruitment into the planned maintenance study due to observed infusion reactions with intermittent infliximab therapy in an unrelated trial. 5 Retrospective cohort studies, typically conducted at referral-centers and thus prone to selection bias, have likewise 2
4 failed to consistently demonstrate a benefit of combination therapy for clinical, biochemical, and endoscopic outcomes over a short duration in both CD and UC. These studies have also not been able to examine patient-important outcomes like hospitalization and surgery over a longer duration of follow-up. 6 In this issue of Clinical Gastroenterology and Hepatology, Targownik and colleagues used an elegant observational comparative effectiveness design in a population-based cohort of patients with IBD to bridge this gap. 7 In a cohort of 852 patients with CD and 303 patients with UC in Manitoba, Canada, the authors compared the effectiveness of combination therapy to TNFα-antagonist monotherapy. Using a novel intent-to-use definition of exposure to combination therapy (either new prescription of immunomodulators within 30 days before or after starting a TNFα-antagonist, or continued refills of immunomodulators after starting a TNFαantagonist in prevalent immunomodulator users), the investigators attempted to mimic an intention to treat model typically used in randomized controlled trials. Upfront combination therapy in new users of TNFα-antagonists with CD was associated with a clinically meaningful 47% lower risk of hospitalization and 37% lower risk of needing biologic switching when compared to those not using anti-tnf monotherapy, along with numerically lower risks of intestinal respective surgery and need for corticosteroids. These benefits were seen regardless of the type of TNFα-antagonist (infliximab or adalimumab) or immunomodulator (thiopurines or methotrexate) used. In contrast, investigators failed to observe a significantly higher effectiveness of upfront combination therapy over TNFα-antagonist monotherapy in patients with UC. These findings were likely impacted by their smaller sample size. These data, from a well-described population-based cohort, provide compelling evidence demonstrating the real-world effectiveness of a strategy of upfront combination therapy over TNFα-antagonist monotherapy in reducing healthcare utilization in patients with CD beyond induction therapy. This is an important addition to our current body of knowledge, as the gap 3
5 between efficacy estimates derived from clinical trials and effectiveness in everyday practice is well described. 8 Several factors may contribute to difficulty in replicating efficacy estimates from clinical trials in the real world, perhaps the most prominent of which is the idealistic design of clinical trials. In order to isolate the effects of a particular therapy being studied, researchers apply strict inclusion and exclusion criteria regarding cohort composition, treatment utilization, and outcome measurement. While this is critical for accurately measuring how efficacious a therapy is when testing new compounds or preparing for regulatory body approval, the application of these criteria significantly limits generalizability: Prior research has demonstrated that only 31% of patients with moderate-to-severely active IBD were eligible for trials at a tertiary center. 9 Patients in clinical practice may have significantly greater variation in age, disease phenotype and severity, prior and concomitant medication use and complications, and comorbidities. Additionally, trials often have a shorter duration of follow-up due to significant costs and are unable to study direct patient-important outcomes like surgery and hospitalization. While trials of novel therapies targeting different disease pathways in IBD continue to be warranted, there is a clear paucity of active head-to-head comparative efficacy trials and pragmatic phase IV trials (of approved therapies) comparing treatment strategies. Such welldesigned trials can reduce inherent bias, but face several significant challenges, as they are more complicated, expensive, and risky for industry sponsors, and budgets for these often exceed what may be feasible for public funding. Observational comparative effectiveness research methods, such as those used in this study, will be vital for bridging the gap between efficacy and effectiveness and informing long-term comparative safety of new therapies and treatment strategies in IBD, as well as informing cost-effectiveness in the real world Observational datasets also have several inherent limitations that must be addressed. Some of these may be overcome through the use of advanced statistical methods and analyses, while others would need to be acknowledged and interpreted appropriately with 4
6 critical evidence synthesis. One foremost challenge is identifying like-for-like patients for comparative effectiveness research, such that both patients have comparable levels of disease severity and distribution of key effect modifiers; if a clinical trial could be performed, then patients could be randomly assigned to either intervention. Propensity score methods, which conceptually evaluate and compare the likelihood (or propensity) of being prescribed a particular treatment approach, can be an important statistical approach to closely replicate true randomization. 17 The propensity score is the probability of treatment assignment conditional on observed baseline characteristics, generated through multinomial logistic regression. There are various applications of propensity score methods that can be applied to assist in identifying likefor-like patients. These approaches have been used in observational comparative effectiveness research in IBD, comparing effectiveness of different TNFα-antagonists 10 and TNF-α antagonists vs. chronic corticosteroids, 11 and comparing safety of TNFα-antagonists and immunomodulators While propensity scores model the risk of exposures, an alternative approach called disease risk scores models the risk of outcome. 18 Disease risk scores model the contribution of independent predictors to the risk of a specific outcome, allowing for multivariable reduction into a single composite measure. They are particularly helpful with newer therapies, in which provider preferences may evolve rapidly, and outcomes may be rare. Observational datasets are also likely to have unmeasured or incompletely measured confounders, which may bias findings that cannot be accounted for by propensity score methods. In these instances, sensitivity analyses using different approaches such as the array method proposed by suggested by Schneeweiss et al may be useful. 19 In this approach, if an incompletely measured (for example, disease severity) or unmeasured confounder (for example, smoking) may preferentially result in prescription of one agent over another, and may influence risk of outcomes, then the probabilistic relationship between the two agents in different scenarios of confounder distribution may be generated to allow conservative interpretation. 5
7 Finally, observational data are also prone to misclassification of exposures and outcomes, both of which can influence effectiveness estimates. Linking diverse datasets, such as electronic medical records, with administrative claims databases and patient registries, through privacypreserving methods, may help minimize the potential impact of misclassification and missingness. 20 In summary, as demonstrated in this novel cohort study, well-designed observational comparative effectiveness research will play an increasingly important role in plugging holes, bridging gaps between trials and real-world, and directly informing clinical practice in IBD in the years to come. REFERENCES: 1. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-tnfalpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013;145: Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362: Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014;146: e1. 4. Matsumoto T, Motoya S, Watanabe K, et al. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. J Crohns Colitis 2016;10: Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146: e3. 6. Dulai PS, Siegel CA, Colombel JF, et al. Systematic review: Monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut 2014;63: Targownik LE, Benchimol EI, Bernstein CN, et al. Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clin Gastroenterol Hepatol 2018; doi: /j.cgh Pagoto SL, Lemon SC. Efficacy vs effectiveness. JAMA Intern Med 2013;173: Ha C, Ullman TA, Siegel CA, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012;10:1002-7; quiz e78. 6
8 10. Singh S, Andersen NN, Andersson M, et al. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. Clin Gastroenterol Hepatol 2017;15: e Lewis JD, Scott FI, Brensinger CM, et al. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol 2018;113: Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology 2018;155: e Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA 2017;318: Scott FI, Mamtani R, Brensinger CM, et al. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol 2016;152: Beilman CL, Kirwin E, Ma C, et al. Early Initiation of Tumor Necrosis Factor Antagonist- Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. Clin Gastroenterol Hepatol 2018; doi: /j.cgh Ma C, Kotze PG, Almutairdi A, et al. Concomitant Use of Aminosalicylates Is Not Associated with Improved Outcomes in Patients with Ulcerative Colitis Escalated to Vedolizumab. Clin Gastroenterol Hepatol 2018; doi: /j.cgh Ertefaie A, Stephens DA. Comparing approaches to causal inference for longitudinal data: inverse probability weighting versus propensity scores. Int J Biostat 2010;6:Article Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf 2012;21 Suppl 2: Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15: Wang S, Jiang X, Singh S, et al. Genome privacy: challenges, technical approaches to mitigate risk, and ethical considerations in the United States. Ann N Y Acad Sci 2017;1387:
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationAccepted Manuscript. Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess
Accepted Manuscript Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess PII: S1542-3565(19)30153-3 DOI: https://doi.org/10.1016/j.cgh.2019.02.013 Reference:
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationAccepted Manuscript. Improving Outcomes in Patients with Inflammatory Bowel Disease through Integrated Multi-Disciplinary Care the Future of IBD Care
Accepted Manuscript Improving Outcomes in Patients with Inflammatory Bowel Disease through Integrated Multi-Disciplinary Care the Future of IBD Care Kaci Christian, MD, Raymond K. Cross, MD, MS PII: S1542-3565(18)30746-8
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265
Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationAccepted Manuscript. Tofacitinib: A jak of all trades. Kristin E. Burke, Ashwin N. Ananthakrishnan
Accepted Manuscript Tofacitinib: A jak of all trades Kristin E. Burke, Ashwin N. Ananthakrishnan PII: S1542-3565(19)30017-5 DOI: https://doi.org/10.1016/j.cgh.2018.12.044 Reference: YJCGH 56279 To appear
More informationFOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015
Contact: Ross Selby Takeda UK Ltd Email ross.selby@takeda.com News Release FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015 World s first gut-selective treatment for ulcerative colitis
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationEvidence review for Surrey Prescribing Clinical Network SUMMARY
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationAnti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Tysabri (natalizumab) MP-042-MD-WV Provider Notice Date: 10/01/2017 Original Effective Date: 11/01/2017 Annual Approval Date:
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 285.8 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationAnti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
Alimentary Pharmacology and Therapeutics Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients A. B. Mohabbat*, W. J. Sandborn, E. V. Loftus Jr, R. H. Wiesner
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationCorporate Medical Policy
Corporate Medical Policy Measurement of Serum Antibodies to Infliximab, Adalimumab and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: measurement_of_serum_antibodies_to_infliximab_and_adalimumab
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationTreatment with Biologic Agents has not Reduced Surgeries among Patients with Crohn s Disease with Short Bowel Syndrome
Accepted Manuscript Treatment with Biologic Agents has not Reduced Surgeries among Patients with Crohn s Disease with Short Bowel Syndrome Berkeley N. Limketkai, MD, PhD, Alyssa M. Parian, MD, Po-Hung
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationPrincipal Investigator. General Information. Certification Published on The YODA Project (
Principal Investigator First Name: William J. Last Name: Sandborn Degree: M.D. Primary Affiliation: University of California San Diego E-mail: wsandborn@ucsd.edu Phone number: 8586575284 Address: 9500
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationModern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions
Modern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions Rami Ismail, Pharm.D., BCPS, BCCCP, CACP Lead Clinical staff Pharmacist, Cleveland Clinic Abu Dhabi Disclosure Information
More informationDeclaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018
Register-based research on safety and effectiveness opportunities and challenges Morten Andersen Department of Drug Design And Pharmacology Declaration of interests Participate(d) in research projects
More informationAccepted Manuscript. Overall and Subgroup Prevalence of Acne Vulgaris Among Patients with Hidradenitis Suppurativa
Accepted Manuscript Overall and Subgroup Prevalence of Acne Vulgaris Among Patients with Hidradenitis Suppurativa Sara Wertenteil, BA, Andrew Strunk, MA, Amit Garg, MD PII: S01909622(18)329128 DOI: https://doi.org/10.1016/j.jaad.2018.11.022
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationEmerging Therapies in IBD: The Future is Bright October 28 th 2017
Emerging Therapies in IBD: The Future is Bright October 28 th 2017 Nirmal Kaur, MD Director, Inflammatory Bowel Disease Center Division of Gastroenterology Henry Ford Health System Disclosures Research
More informationTechnology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352
Vedolizumab for treating moderately to severely erely active Crohn's disease after prior therapy Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352 NICE 2017. All rights
More informationBridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists
ORIGINAL ARTICLE Annals of Gastroenterology (2017) 30, 1-5 Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists Mohammad
More informationAmjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65
Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationPharmacy Management Drug Policy
SUBJECT: Multiple Sclerosis, Crohn s Disease POLICY NUMBER: PHARMACY-53 EFFECTIVE DATE: 4/08 LAST REVIEW DATE: 12/18/2018 If the member s subscriber contract excludes coverage for a specific service or
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationTherapeutic Drug Monitoring και ΙΦΝΕ το 2018
Therapeutic Drug Monitoring και ΙΦΝΕ το 2018 TDM: Ναι το χρειαζόμαστε, σε όλους και πάντοτε Κωνσταντίνος Κατσάνος Conflict of interest By means of this, the speaker confirms that he receives honoraria
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07.16 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationOnce Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis
Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University JKM 2014 Svartz N. Acta Med Scand
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Annals of Gastroenterology (2014) 27, 1-5 Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first real-life experience in
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationDiagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Children with Inflammatory Bowel Disease
Diagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Children with Inflammatory Bowel Disease Lena B. Palmer MD, Carol Q. Porter, Michael D. Kappelman MD MPH No relevant financial disclosures
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationMalignancy Risk in Pediatric IBD: What to tell parents and patients?
Malignancy Risk in Pediatric IBD: What to tell parents and patients? Corey A. Siegel, MD, MS Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical Center Digestive Disease Week 2017 Chicago,
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationGuide to Gastroenterology Biological Therapeutic Drug Monitoring Pathway (TDM)
Guide to Gastroenterology Biological Therapeutic Drug Monitoring Pathway (TDM) Author: Responsible Lead Consultants: Endorsing Body: Implementation Date: 01/08/2018 Version Number: 1.0 Review Date: 01/08/2020
More informationvedolizumab 300mg powder for concentrate for solution for infusion (Entyvio ) SMC No. (1064/15) Takeda UK Ltd
vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio ) SMC No. (1064/15) Takeda UK Ltd 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationInfliximab Therapy in Pediatric Patients 7 Years of Age and Younger
ORIGINAL ARTICLE: GASTROENTEROLOGY Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger Judith R. Kelsen, Andrew B. Grossman, Helen Pauly-Hubbard, Kernika Gupta, Robert N. Baldassano, and
More informationScottish Medicines Consortium
Scottish Medicines Consortium infliximab 100mg powder for intravenous infusion (Remicade ) No. (364/07) Schering-Plough UK Ltd 6 April 2007 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationEffective Health Care Program
Comparative Effectiveness Review Number 131 Effective Health Care Program Pharmacologic Therapies for the Management of Crohn s Disease: Comparative Effectiveness Executive Summary Description of Crohn
More informationOxford Inflammatory Bowel Disease MasterClass. What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France
Oxford Inflammatory Bowel Disease MasterClass What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France Disclosures Consulting and/or lecture fees from Merck, Abbott,
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd
ustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd 09 June 2017 The Scottish Medicines Consortium (SMC) has completed
More information2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1054. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationAssociation Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease
Research Original Investigation Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease Nynne Nyboe Andersen, MD; Björn Pasternak, MD, PhD;
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationAccepted Manuscript. Correlation or Causation: Sex Hormones and Microscopic Colitis. Baldeep Pabla, Reid M. Ness
Accepted Manuscript Correlation or Causation: Sex Hormones and Microscopic Colitis Baldeep Pabla, Reid M. Ness PII: S0016-5085(18)35216-8 DOI: https://doi.org/10.1053/j.gastro.2018.11.007 Reference: YGAST
More informationTechnology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547
Tofacitinib for moderately to severelyerely active ulcerative colitis Technology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547 NICE 2019. All rights reserved. Subject to Notice
More information